MARKET

LIPO

LIPO

Lipella Pharmaceuticals Inc
NASDAQ
2.400
-0.029
-1.18%
Closed 17:05 05/09 EDT
OPEN
2.380
PREV CLOSE
2.429
HIGH
2.500
LOW
2.380
VOLUME
5.26K
TURNOVER
3.39M
52 WEEK HIGH
12.00
52 WEEK LOW
1.965
MARKET CAP
6.12M
P/E (TTM)
-0.5015
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LIPO last week (0505-0509)?
Weekly Report · 55m ago
Weekly Report: what happened at LIPO last week (0428-0502)?
Weekly Report · 05/05 10:14
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 04/28 21:05
Weekly Report: what happened at LIPO last week (0421-0425)?
Weekly Report · 04/28 10:19
Lipella Reports Statistically Significant Results from Second Cohort in LP-310 Phase 2a Trial for Oral Lichen Planus
TipRanks · 04/23 16:00
Lipella abstract on LP-10 for OLP accepted for presentation at AAOM, EAOM
TipRanks · 04/23 12:47
Lipella Pharmaceuticals To Present Abstract On Oral Lichen Planus Treatment At 2025 AAOM/EAOM International Meeting Conference On "Global Transformation in Oral Medicine"
Benzinga · 04/23 12:35
Lipella Pharmaceuticals announces results from second cohort of LP-310 trial
TipRanks · 04/22 09:46
More
About LIPO
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The Company is addressing two indications via the development of its product candidates, which it has designated as LP-10 for the indication of hemorrhagic cystitis (HC) and LP-310 for the indication of oral lichen planus (OLP), which is chronic, uncontrolled urinary blood loss that results from certain chemotherapies (such as alkylating agents) or pelvic radiation therapy (also called radiation cystitis). In the third program, the Company is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). In a fourth program, the Company is also developing an intravesical formulation of immunoglobulins including checkpoint inhibitors, referred to as LP-50.

Webull offers Lipella Pharmaceuticals Inc stock information, including NASDAQ: LIPO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIPO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LIPO stock methods without spending real money on the virtual paper trading platform.